Search results
Results From The WOW.Com Content Network
Effects have included an increase in cannabis-related calls to the Oregon state poison center, [29] an increase in perception among youth that marijuana use is harmful, [29] a decrease in arrest rates for cannabis related offenses, [29] stores sold $250 million in cannabis products which resulted in $70 million in state tax revenue (higher than ...
A 2013 literature review said that exposure to cannabis was "associated with diseases of the liver (particularly with co-existing hepatitis C), lungs, heart, and vasculature". The authors cautioned that "evidence is needed, and further research should be considered, to prove causal associations of marijuana with many physical health conditions ...
A dried cannabis flower. The short-term effects of cannabis are caused by many chemical compounds in the cannabis plant, including 113 [clarification needed] different cannabinoids, such as tetrahydrocannabinol, and 120 terpenes, [1] which allow its drug to have various psychological and physiological effects on the human body.
Laboratory experiments have shown that cannabinoids found in marijuana may have analgesic and anti-inflammatory effects. [23] In 2014, the American Academy of Neurology reviewed all available findings levering the use of marijuana to treat brain diseases. The result was that the scientific evidence is weak that cannabis in any form serves as ...
According to Business Insider, only 6% of studies on marijuana focused on the drug's benefits. But there are so many.
Story at a glance Marijuana for medical use has been legalized in many states. Cancer patients in particular may benefit from medical marijuana for managing pain and symptoms. An analysis of ...
Marijuana is already commonly used to alleviate some of the painful symptoms of cancer and chemotherapy, but there's some research suggesting marijuana can actually delay or reduce tumors.
While marijuana has been decriminalized throughout many states in the US, it remains a Schedule I drug as of October 2024. However, on January 12, 2024, the FDA announced its recommendation that marijuana be moved to a Schedule III drug, which is a much less strictly-regulated category and would acknowledge its potential for medical use. [67]